Floatz logo

egf816

Soft Tissue Sarcoma

Cancer Research UKSmall moleculePhase 2/3Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
81/ 100

Competitive context

44 Active assets in the Soft Tissue Sarcoma cohort.

Asset / SponsorPhaseRating
Inno-206
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3BB
Cyclophosphamide
Medigene AG
Phase 2BB
Tislelizumab
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3BB
Durvalumab
Institut Bergonié
Phase 2B
ETOPOSIDE
Masonic Cancer Center, University of Minnesota
Phase 2B

View all 50 →

Same molecule, other indications

egf816 is also rated in:

Carcinoma, Non-Small-Cell LungDormant
CCC
Indicative ·
52 / 100
View asset →
non-small cell lung carcinomaDormant
CCC
Indicative ·
49 / 100
View asset →
non-small cell lung carcinomaDormant
CCC
Indicative ·
49 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →